Published in J Clin Oncol on July 15, 2001
Efficacy of Letrozole in Recurrent Ovarian Cancer (MITO32) | NCT04421547
Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol (2010) 7.26
Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res (2011) 2.85
The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers. Nat Mater (2011) 2.84
Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci U S A (2007) 2.61
Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin (2011) 2.57
Trends in relative survival for ovarian cancer from 1975 to 2011. Obstet Gynecol (2015) 2.22
History of the Baylor Charles A. Sammons Cancer Center. Proc (Bayl Univ Med Cent) (2003) 2.15
Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol (2012) 2.14
Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J Clin Oncol (2009) 2.07
Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin. Br J Cancer (2004) 1.67
Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. J Control Release (2013) 1.64
State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines. J Control Release (2014) 1.46
Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials. Gynecol Oncol (2007) 1.44
Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation. Int J Nanomedicine (2007) 1.37
Cancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers. Adv Mater (2011) 1.33
Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J Clin Oncol (2010) 1.26
Palmar-plantar erythrodysesthesia associated with chemotherapy and its treatment. Case Rep Oncol (2011) 1.22
Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial. Gynecol Oncol (2009) 1.18
S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013. Geburtshilfe Frauenheilkd (2013) 1.15
Pegylated liposomal doxorubicin in ovarian cancer. Int J Nanomedicine (2006) 1.13
Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma. BMC Cancer (2003) 1.11
Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer (2012) 1.11
Challenges associated with Penetration of Nanoparticles across Cell and Tissue Barriers: A Review of Current Status and Future Prospects. Nano Today (2014) 1.09
Liposomal Doxorubicin in the treatment of breast cancer patients: a review. J Drug Deliv (2013) 1.09
Treatment for recurrent ovarian cancer-at first relapse. J Oncol (2009) 1.08
Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer. Br J Cancer (2009) 1.07
Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice. J Control Release (2013) 1.06
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. Cancer Discov (2015) 1.06
A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer (2007) 1.05
Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Ther Adv Med Oncol (2014) 1.05
A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecol Oncol (2011) 1.01
Cancer treatment according to BRCA1 and BRCA2 mutations. Nat Rev Clin Oncol (2012) 1.01
Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with Paclitaxel and Carboplatin leads to receptor-mediated antiproliferative effects. J Cancer Res Clin Oncol (2008) 0.99
The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges. Chin J Cancer (2015) 0.99
Design considerations for nanotherapeutics in oncology. Nanomedicine (2015) 0.96
Major clinical research advances in gynecologic cancer in 2012. J Gynecol Oncol (2013) 0.96
Metformin, at concentrations corresponding to the treatment of diabetes, potentiates the cytotoxic effects of carboplatin in cultures of ovarian cancer cells. Reprod Sci (2013) 0.94
Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer. Curr Opin Oncol (2012) 0.94
Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma. Gynecol Oncol (2011) 0.93
Biological rationale for the design of polymeric anti-cancer nanomedicines. J Drug Target (2012) 0.93
Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer. Br J Cancer (2003) 0.93
Clinical Translation of Nanomedicine. Chem Rev (2015) 0.93
Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours. Br J Cancer (2014) 0.92
Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women's cancers. Results of a prospective study. Support Care Cancer (2007) 0.91
Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain. Br J Cancer (2003) 0.90
Triapine disrupts CtIP-mediated homologous recombination repair and sensitizes ovarian cancer cells to PARP and topoisomerase inhibitors. Mol Cancer Res (2014) 0.90
Treatment of recurrent epithelial ovarian cancer. Ther Clin Risk Manag (2009) 0.90
Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer. Br J Cancer (2011) 0.90
A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer. Br J Cancer (2002) 0.89
Clinical trials and progress with paclitaxel in ovarian cancer. Int J Womens Health (2010) 0.89
Outcomes analysis of an alternative formulation of PEGylated liposomal doxorubicin in recurrent epithelial ovarian carcinoma during the drug shortage era. Onco Targets Ther (2014) 0.89
Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group. Br J Cancer (2009) 0.88
A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261. Gynecol Oncol (2012) 0.87
Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer. World J Surg (2004) 0.87
Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial. BMC Cancer (2006) 0.87
A phase I study of irinotecan and pegylated liposomal doxorubicin in recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study). Cancer Chemother Pharmacol (2014) 0.86
Pegylated liposomal doxorubicin in the management of ovarian cancer: a systematic review and metaanalysis of randomized trials. Cancer Biol Ther (2014) 0.86
Clinical trial designs for testing biomarker-based personalized therapies. Clin Trials (2012) 0.86
Can nanomedicines kill cancer stem cells? Adv Drug Deliv Rev (2013) 0.86
Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer. Pharmgenomics Pers Med (2013) 0.86
Urokinase plasminogen activator system-targeted delivery of nanobins as a novel ovarian cancer therapy. Mol Cancer Ther (2013) 0.86
Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives. Int J Womens Health (2016) 0.85
Major clinical research advances in gynecologic cancer in 2010. J Gynecol Oncol (2010) 0.85
Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer. Onco Targets Ther (2014) 0.85
(18)F-FDG Is a Surrogate Marker of Therapy Response and Tumor Recovery after Drug Withdrawal during Treatment with a Dual PI3K/mTOR Inhibitor in a Preclinical Model of Cisplatin-Resistant Ovarian Cancer. Transl Oncol (2013) 0.85
Pegylated liposomal doxorubicin in the management of ovarian cancer. Ther Clin Risk Manag (2010) 0.85
Ovarian cancer treatment: The end of empiricism? Cancer (2015) 0.85
Serum biomarkers for personalization of nanotherapeutics-based therapy in different tumor and organ microenvironments. Cancer Lett (2013) 0.85
Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer. Cancer Manag Res (2011) 0.85
Biological significance of HORMA domain containing protein 1 (HORMAD1) in epithelial ovarian carcinoma. Cancer Lett (2012) 0.85
A liposomal drug platform overrides peptide ligand targeting to a cancer biomarker, irrespective of ligand affinity or density. PLoS One (2013) 0.85
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol (2016) 0.84
A mathematical model of the enhanced permeability and retention effect for liposome transport in solid tumors. PLoS One (2013) 0.84
A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers. Gynecol Oncol (2009) 0.84
Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study. Gynecol Oncol (2008) 0.84
The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies. Front Oncol (2013) 0.84
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come. Pharmacol Rev (2016) 0.84
Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. Gynecol Oncol (2016) 0.84
Long-term pegylated liposomal doxorubicin use in recurrent ovarian carcinoma. J Natl Med Assoc (2005) 0.83
Clinical trials with pegylated liposomal Doxorubicin in the treatment of ovarian cancer. J Drug Deliv (2013) 0.83
The role of hormonal factors and endocrine therapy in ovarian cancer. Contemp Oncol (Pozn) (2013) 0.83
Early detection of tumor response by FLT/microPET Imaging in a C26 murine colon carcinoma solid tumor animal model. J Biomed Biotechnol (2011) 0.83
Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: a 2-cohort, phase 2 study. Cancer (2011) 0.83
The Emerging Role of PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer. J Oncol (2009) 0.82
Phase 1/2 study of atrasentan combined with pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer. Neoplasia (2010) 0.81
A phase 2 study of oxaliplatin combined with continuous infusion topotecan for patients with previously treated ovarian cancer. Int J Gynecol Cancer (2013) 0.81
Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer. Invest New Drugs (2003) 0.81
Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes. Ann Oncol (2009) 0.80
High cumulative doses of pegylated liposomal doxorubicin are not associated with cardiac toxicity in patients with gynecologic malignancies. Chemotherapy (2010) 0.80
Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary. Ann Oncol (2010) 0.80
A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it? J Ovarian Res (2013) 0.80
Evaluation of pegylated liposomal doxorubicin dose on the adverse drug event profile and outcomes in treatment of recurrent endometrial cancer. Int J Gynecol Cancer (2013) 0.80
Computational analysis of drug transport in tumor microenvironment as a critical compartment for nanotherapeutic pharmacokinetics. Drug Deliv (2015) 0.80
Feasibility study of oral cyclophosphamide salvage therapy for the treatment of heavily pretreated patients with recurrent epithelial ovarian cancer. Int J Clin Oncol (2010) 0.80
Multistage nanoparticles for improved delivery into tumor tissue. Methods Enzymol (2012) 0.79
Combination chemotherapy with carboplatin, capecitabine and epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer: a phase I/II trial. Br J Cancer (2006) 0.79
A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies. Cancer Chemother Pharmacol (2012) 0.79
Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol (1989) 6.86
Randomised trial of hysterectomy, endometrial laser ablation, and transcervical endometrial resection for dysfunctional uterine bleeding. BMJ (1994) 5.76
U.K. guidelines for the management of cutaneous melanoma. Br J Dermatol (2002) 4.92
The retardation of aging in mice by dietary restriction: longevity, cancer, immunity and lifetime energy intake. J Nutr (1986) 4.81
The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med (1995) 4.75
Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet (2001) 4.16
UK guidelines for the management of cutaneous melanoma. Br J Plast Surg (2002) 3.51
Infectious complications of subcutaneous interleukin-2 and interferon-alpha. Lancet (1992) 2.65
Natural history of stage IV epithelial ovarian cancer. J Clin Oncol (1999) 2.52
Malignant melanoma. Effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later. Arch Gen Psychiatry (1993) 2.38
Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. Br J Dermatol (2012) 2.23
Revised U.K. guidelines for the management of cutaneous melanoma 2010. Br J Dermatol (2010) 2.22
Two-year follow up of women randomised to medical management or transcervical resection of the endometrium for heavy menstrual loss: clinical and quality of life outcomes. Br J Obstet Gynaecol (1999) 2.16
Management of metastatic melanoma during pregnancy. BMJ (1998) 2.10
A randomised comparison of medical and hysteroscopic management in women consulting a gynaecologist for treatment of heavy menstrual loss. Br J Obstet Gynaecol (1997) 2.10
Effect sizes and p values: what should be reported and what should be replicated? Psychophysiology (1996) 2.07
Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer (1997) 2.04
Ovarian cancers related to minimal access surgery. Br J Obstet Gynaecol (1995) 2.02
When the earth stops shaking: earthquake sequelae among children diagnosed for pre-earthquake psychopathology. J Am Acad Child Adolesc Psychiatry (1999) 2.01
Randomised trial comparing hysterectomy with endometrial ablation for dysfunctional uterine bleeding: psychiatric and psychosocial aspects. BMJ (1996) 2.00
Natural history and prognosis of untreated stage I epithelial ovarian carcinoma. J Clin Oncol (1996) 1.78
THE ADVANTAGES OF THE PRIMARY SUPERIOR POLAR ATTACK IN THE REMOVAL OF SUBSTERNAL THYROIDS. Ann Surg (1926) 1.70
Vineland Adaptive Behavior Scale scores as a function of age and initial IQ in 210 autistic children. J Autism Dev Disord (1999) 1.66
Lower Purkinje cell counts in the cerebella of four autistic subjects: initial findings of the UCLA-NSAC Autopsy Research Report. Am J Psychiatry (1986) 1.65
Methods to assess population effectiveness of therapies in human immunodeficiency virus incident and prevalent cohorts. Am J Epidemiol (2001) 1.55
Chemotherapy for symptom control in recurrent squamous cell carcinoma of the head and neck. Ann Oncol (1997) 1.53
A multicenter phase II clinical trial using dacarbazine and continuous infusion interleukin-2 for metastatic melanoma. Clinical data and immunomonitoring. Cancer (1995) 1.52
Indolent cutaneous prodrome of fatal HTLV-I infection. Lancet (1990) 1.48
Carboplatin (Paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancer. J Clin Oncol (1987) 1.47
Differential effects of women's child sexual abuse and subsequent sexual revictimization. J Consult Clin Psychol (1992) 1.47
p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res (1993) 1.45
Tamoxifen and chemotherapy for refractory metastatic malignant melanoma. N Engl J Med (1993) 1.38
Phase I and pharmacokinetic studies with the pentacyclic pyrroloquinone mitoquidone. Cancer Chemother Pharmacol (1988) 1.38
Predictors of posttraumatic stress symptoms in childhood cancer survivors. Pediatrics (1997) 1.37
One-year outcomes of depressive disorders in child psychiatric in-patients: evaluation of the prognostic power of a brief measure of expressed emotion. J Child Psychol Psychiatry (1993) 1.35
Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol (1996) 1.33
Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer. Eur J Obstet Gynecol Reprod Biol (2007) 1.29
Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer (1998) 1.27
Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma. Br J Cancer (2013) 1.24
Osseous metaplasia of the endometrium treated by hysteroscopic resection. Br J Obstet Gynaecol (1993) 1.21
X. Congenital Unilateral Absence of the Urogenital System. Ann Surg (1909) 1.20
Chemotherapy for ovarian cancer--a consensus statement on standard practice. Br J Cancer (1998) 1.19
Measures of psychopathology in children with complex partial seizures and primary generalized epilepsy with absence. J Am Acad Child Adolesc Psychiatry (2001) 1.18
Revised UK guidelines for the management of cutaneous melanoma 2010. J Plast Reconstr Aesthet Surg (2010) 1.16
Carbamazepine as an anticonvulsant in children. Neurology (1977) 1.15
Relation between raised concentrations of fucose, sialic acid, and acute phase proteins in serum from patients with cancer: choosing suitable serum glycoprotein markers. J Clin Pathol (1985) 1.15
Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma. Oral Oncol (1997) 1.15
Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol (1995) 1.15
Kinsey revisited, Part II: Comparisons of the sexual socialization and sexual behavior of black women over 33 years. Arch Sex Behav (1988) 1.15
Predicting posttraumatic stress symptoms in mothers and fathers of survivors of childhood cancers. J Am Acad Child Adolesc Psychiatry (1998) 1.15
Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer (2000) 1.13
Levels of adenosine 3',5' cyclic monophosphate and guanosine 3',5' cyclic monophosphate in single urine specimens collected from a large population of healthy subjects. Ann Clin Biochem (1982) 1.11
Family-expressed emotion, childhood-onset depression, and childhood-onset schizophrenia spectrum disorders: is expressed emotion a nonspecific correlate of child psychopathology or a specific risk factor for depression? J Abnorm Child Psychol (1994) 1.10
A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma. Br J Cancer (2011) 1.10
Coping strategies, self-perceptions, hopelessness, and perceived family environments in depressed and suicidal children. J Consult Clin Psychol (1987) 1.09
Treatment of nondysgerminomatous ovarian germ cell tumors: an analysis of 69 cases. Cancer (1999) 1.08
Mucinous ovarian cancer. Int J Gynecol Cancer (2007) 1.07
Improving access to diagnostics: an evaluation of a satellite laboratory service in the emergency department. Emerg Med J (2004) 1.07
The early development of autistic children. J Autism Child Schizophr (1977) 1.06
Prepulse inhibition of startle and the neurobiology of primary nocturnal enuresis. Biol Psychiatry (1999) 1.05
A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer (2007) 1.05
Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann Oncol (2003) 1.04
Growth and maturation of children with insulin-dependent diabetes mellitus. Diabetes Care (1979) 1.04
Thought disorder in attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry (2001) 1.03
A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily. Br J Cancer (1996) 1.03
A prognostic index that predicts outcome following palliative whole brain radiotherapy for patients with metastatic malignant melanoma. Br J Cancer (2004) 1.01
Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel. J Clin Oncol (1999) 1.01
Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. J Clin Oncol (2000) 1.01
Hemispherectomy for intractable seizures: presurgical cerebral glucose metabolism and post-surgical non-verbal communication. Dev Med Child Neurol (1993) 1.01
Carcinosarcoma of the ovary: incidence, prognosis, treatment and survival of patients. Ann Oncol (1995) 1.00
Long-term habituation and sensitization of the acoustic startle response in the normal adult human. Psychophysiology (1989) 0.99
Behavioral characteristics of high- and low-IQ autistic children. Am J Psychiatry (1981) 0.98
Maturation of startle modulation. Psychophysiology (1986) 0.98
Brain stem auditory evoked response development in the kitten. Brain Res (1980) 0.97
Midlatency auditory evoked responses: P1 abnormalities in adult autistic subjects. Electroencephalogr Clin Neurophysiol (1992) 0.97
Immunotherapy of non-clinical vaginal cancer. Lancet (1975) 0.97
Human papillomavirus 16 infection in adenocarcinoma of the cervix. Br J Cancer (2005) 0.96
Sex, pregnancy, hormones, and melanoma. BMJ (1993) 0.96
Family responses to children with early developmental delays. II: Accommodation intensity and activity in early and middle childhood. Am J Ment Retard (1996) 0.96
Aggressive management of doxorubicin-induced cardiomyopathy associated with 'low' doses of doxorubicin. Postgrad Med J (1994) 0.96
A pragmatic randomised comparison of transcervical resection of the endometrium with endometrial laser ablation for the treatment of menorrhagia. Br J Obstet Gynaecol (1997) 0.96
Screening by the prostate-specific antigen test: what do the patients know? J Cancer Educ (1996) 0.95
Granulosa cell tumours of the ovary: demographics, survival and the management of advanced disease. Clin Oncol (R Coll Radiol) (1998) 0.95
The significance of paracardiac lymph node enlargement in ovarian cancer. Clin Radiol (1997) 0.94
Propylene glycol pharmacokinetics and effects after intravenous infusion in humans. Ther Drug Monit (1987) 0.94
Thought disorder in childhood schizophrenia: replication and update of concept. J Am Acad Child Adolesc Psychiatry (2000) 0.94
Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma. Br J Cancer (1998) 0.94
Blink rate in children with attention-deficit-hyperactivity disorder. Biol Psychiatry (1996) 0.94
Cerebellar vermis lobules VIII-X in autism. Prog Neuropsychopharmacol Biol Psychiatry (1999) 0.94
Disturbance of blood-brain barrier after bone-marrow transplantation. Lancet (1985) 0.93
Conversational repair in schizophrenic and normal children. J Am Acad Child Adolesc Psychiatry (1996) 0.93
The Kiddie Formal Thought Disorder Rating Scale: clinical assessment, reliability, and validity. J Am Acad Child Adolesc Psychiatry (1989) 0.93
Lipoprotein and apoprotein levels in postmenopausal women during treatment with norethisterone. Clin Chim Acta (1986) 0.93
Outcome of pregnancies complicated by early vaginal bleeding. Br J Obstet Gynaecol (1980) 0.93
Medial temporal lobe in childhood-onset schizophrenia. Psychiatry Res (2001) 0.92
Maturation of prestimulation-induced startle modulation in girls. Psychophysiology (1991) 0.92
Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit. Br J Cancer (1990) 0.92